Aquatic Capital Management LLC Raises Position in Boston Scientific Co. (NYSE:BSX)

Aquatic Capital Management LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 163,410 shares of the medical equipment provider's stock after buying an additional 10,510 shares during the quarter. Aquatic Capital Management LLC's holdings in Boston Scientific were worth $14,596,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. TFC Financial Management Inc. grew its position in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares during the period. Global Wealth Strategies & Associates grew its position in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares during the period. West Oak Capital LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $29,000. Valley National Advisers Inc. lifted its holdings in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Wells Fargo & Company increased their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Piper Sandler increased their target price on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of "Buy" and an average price target of $114.52.

Insider Activity

In other news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares of the company's stock, valued at $2,704,845.33. This represents a 4.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the sale, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock worth $14,407,381 over the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

NYSE BSX traded up $0.51 during trading on Tuesday, hitting $102.69. 5,478,642 shares of the company's stock traded hands, compared to its average volume of 6,347,135. The stock has a market capitalization of $151.89 billion, a price-to-earnings ratio of 82.15, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 12-month low of $70.97 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The business has a 50 day moving average of $98.62 and a 200-day moving average of $95.03.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. The company's revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.